Alzheimer's drug wins priority review in Japan
Biogen and Eisai ’s Alzheimer’s treatment candidate gains access to faster case processing by authorities in Japan.
by ulrich quistgaard, translated by daniel pedersen
The Japanese health authority has granted its priority review status to lecanemab indicated for Alzheimer’s treatment, ensuring faster case processing before potential approval.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
